Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

LabGenomics Co., Ltd. engages in the provision of vitro diagnostic products and services. Its products include sample and bioinformatics analysis, diagnostic checks, and other products. The company was founded on March 29, 2002 and is headquartered in Seongnam-si, South Korea.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Sysmex Corp. engages in the healthcare business. It develops, manufactures, sells, exports, and imports diagnostic instruments, reagents. and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing. It operates through the following geographical segments: Japan, Americas, Europe, Middle East, and Africa (EMEA), China, and Asia Pacific. The company was founded by Taro Nakatani on February 20, 1968 and is headquartered in Kobe, Japan.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Guangzhou Burning Rock Medical Laboratory Co., Ltd., established on 2014-03-18, Business scope includes manufacturing of information chemicals(Monitor Chemicals,Excluding hazardous chemicals);Medical Research and Experimental Development;Instrument wholesale;General Machinery Sales;Medical supplies and equipment retail(Does not contain drugs and medical devices);Machinery and Equipment Leasing;computer retail;software retail;Medical equipment rental service;Sales of electrical machinery and equipment;Sales of chemical reagents and auxiliaries(Monitor Chemicals,Excluding hazardous chemicals);Special Equipment Sales;Chemical Reagent and Auxiliary Manufacturing(Monitor Chemicals,Excluding hazardous chemicals);Manufacturing of special chemicals(Monitor Chemicals,Excluding hazardous chemicals);Manufacturing of other non-hazardous basic chemical raw materials;Manufacturing of experimental analysis instruments;Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;software development;Import and export(Excluding franchised products);Technology Import and Export;Operation of non-licensed medical devices;Clinical Laboratory Services;medical diagnosis,Monitoring and treatment equipment wholesale;medical diagnosis,Monitoring and treatment equipment retail;Monitor Chemical Manufacturing;medical diagnosis,Monitoring and treatment equipment manufacturing;Manufacturing of medical laboratory equipment and appliances;Production of medical electronic equipment(The specific production range is<Medical Device Manufacturing Enterprise License>prevail);Licensed medical device business

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Shanghai Rendong Medical Laboratory Co., Ltd., established on 2011-12-21, Business scope includes for-profit medical institutions,Engaged in technology development in the field of biotechnology,technology transfer,technical consulting,Technical Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Acornmed provides tumor genetic testing and detection solutions intended to provide clinical solutions with genomics as the core of tumor precision medicine. It also provides advanced molecular diagnosis for solid and blood tumor genetic testing, enabling cancer patients to receive comprehensive and personalized early detection test results.

Beijing Oak Xin Medical Technology Co., Ltd., established on 2018-12-18, Business scope includes technology development,Technical Services,technology transfer,Technology Promotion,technical consulting;software development;software consulting;Health Advisory(Except for medical treatment activities subject to approval);sell electronics,chemical reagent,Chemical Products,computer,Software and Auxiliary Equipment,Equipment;Undertake exhibition and display activities;market survey;computer graphic design;product design;design,make,acting,Place an ad;Conference Services;translation service;Application software service;Computer System Services;Basic software service;internet data service(Data Centers in Internet Data Services,PUEvalue in1.4Except for the above cloud computing data centers);Information processing and storage support services(Data centers in information processing and storage support services,PUEvalue in1.4Except for the above cloud computing data centers);Natural science research and experimental development;Medical Research and Experimental Development;Sales Class I,Class II medical device;Sales of Class III medical devices.(Enterprises independently choose operating projects according to law,Carry out business activities;Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.